Clinical Edge Journal Scan

Obesity and metabolic syndrome at younger ages may increase earlier-onset CRC risk


 

Key clinical point: Metabolic syndrome (MetS) and obesity in individuals aged between 20 and 49 years are associated with an increased risk for earlier-onset colorectal cancer (CRC).

Major finding: MetS (adjusted hazard ratio [aHR] 1.20; 95% CI 1.14-1.27) and a higher body mass index (BMI; 25.0-29.9 kg/m 2: aHR 1.19; 95% CI 1.12-1.25; ≥30 kg/m 2: aHR 1.45; 95% CI 1.31-1.61) and waist circumference (WC; ≥100 cm in men or ≥95 cm in women: aHR 1.53; 95% CI 1.34-1.74) were associated with an increased earlier-onset CRC risk.

Study details: Findings are from a nationwide population-based cohort study that enrolled 5,672,153 individuals aged 20-49 years with health checkup data (i.e., anthropometric measurement, laboratory test, and health behavior data), of which 8320 developed earlier-onset CRC.

Disclosures: The study received no funding. The authors declared no conflicts of interest.

Source: Jin EH et al. Association between metabolic syndrome and the risk of colorectal cancer diagnosed before 50 years according to tumor location. Gastroenterology. 2022 (May 26). Doi: 10.1053/j.gastro.2022.05.032

Recommended Reading

AGA issues position statements on reducing CRC burden
MDedge Hematology and Oncology
New treatment reduces risk of anal cancer in people with HIV
MDedge Hematology and Oncology
Intensified chemotherapy confers no additional benefits with panitumumab in RAS and BRAF wt mCRC
MDedge Hematology and Oncology
Atezolizumab added to FOLFOXIRI + bevacizumab seems safe and beneficial in previously untreated mCRC
MDedge Hematology and Oncology
Therapy trends in patients with mCRC after the second disease progression
MDedge Hematology and Oncology
Is iatrogenic tumor seeding a risk factor for metachronous CRC? Evidence suggests otherwise
MDedge Hematology and Oncology
Heavy drinking associated with increased risk for EOCRC irrespective of genetic risk
MDedge Hematology and Oncology
Refractory metastatic CRC: Raltitrexed plus S-1 betters regorafenib in prolonging survival
MDedge Hematology and Oncology
CRC with synchronous liver metastases: Outcomes of simultaneous laparoscopic vs. hybrid and open resection
MDedge Hematology and Oncology
Does high consumption of nuts and legumes protect against CRC?
MDedge Hematology and Oncology